Venetoclax‐Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence
European Journal of Haematology · 2026-07 · 117 (1) · 117-131
DOI: 10.1111/ejh.70189 ↗Kurz gefasst
Scoping Review in der Zeitschrift European Journal of Haematology, online erschienen am 31.03.2026. Verfasst von Mohammed Abdulgayoom und 5 weiteren Autor:innen. Beteiligte Einrichtung: Haematology/BMT Department, National Center for Cancer Care and Research, HMC, Doha, Qatar. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation Conditioning, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains the only potentially curative therapy for many patients with high‐risk myeloid neoplasms, yet relapse and transplant‐related toxicity continue to limit durable benefit. Venetoclax (VEN), a selective BCL‐2 inhibitor, provides a biologically compelling strategy for conditioning augmentation through chemotherapy sensitization and potential lowering of host immune resistance to engraftment. We performed a hybrid scoping review and evidence‐mapping analysis to summarize published clinical experience and the active investigational landscape of VEN‐containing conditioning or sequential regimens prior to allo‐HSCT. Eighteen studies (20 reports) met the inclusion criteria, including nine published cohorts comprising 238 patients and 11 ongoing clinical trials. Reported platforms were heterogeneous, spanning reduced‐intensity, myeloablative, and sequential approaches. Engraftment and graft‐versus‐host disease outcomes were generally comparable to expected benchmarks, although available data remain preliminary and non‐randomized, underscoring that the primary aim of this scoping review is to map existing evidence and ongoing trials rather than to inform clinical practice or guideline recommendations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haematology/BMT Department, National Center for Cancer Care and Research, HMC, Doha, Qatar.
- Pharmacy Department, National Center for Cancer Care and Research, HMC, Doha, Qatar.
ORCID-Profile: Mohammed Abdulgayoom, Awni Alshurafa, Shehab F Mohamed
Zitieren
APA
Abdulgayoom, M., Gulied, A., Alshurafa, A., Mohamed, S. F., Yassin, M. A., & Fadul, A. (2026). Venetoclax‐Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence. European Journal of Haematology, 117(1), 117-131. https://doi.org/10.1111/ejh.70189
Vancouver
Abdulgayoom M, Gulied A, Alshurafa A, Mohamed SF, Yassin MA, Fadul A. Venetoclax‐Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence. European Journal of Haematology. 2026;117(1):117-131. doi:10.1111/ejh.70189
BibTeX
@article{Abdulgayoom2026,
author = {Abdulgayoom, Mohammed and Gulied, Amaal and Alshurafa, Awni and Mohamed, Shehab F and Yassin, Mohamed A and Fadul, Afraa},
title = {Venetoclax‐Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence},
journal = {European Journal of Haematology},
year = {2026},
volume = {117},
number = {1},
pages = {117--131},
doi = {10.1111/ejh.70189}
}
EUVIMED